Skip to main content

Study of interaction between stent, arterial wall and blood related to atherosclerosis disease.

This project will target 2 main aspects, on the one hand the metal effect on thrombogenecity, which leads to hyperplasia and restenosis, on the other hand the effect of the multilayer stent on the shear stress flow which prevents hyperplasia. Several studies show that the thrombogenicity of the metal could be prevented by covering it with a non-thrombogenic biocompatibility nanofilm. The outcome of this project will have major impacts:

  • Clinically: the device has a non-thrombogenic metal surface, which ensures long-term patency.
  • Cardiatis’ development: the company intends to become a leader in the treatment of cerebral and peripheral aneurysm by stenting. To our knowledge, Cardiatis is the only company developing such a device for the treatment of cerebral aneurysm (saccular and bifurcated) without coil and a non-covered stent allowing to heal all other peripheral aneurysms.
  • Image and partnership: Cardiatis aims at becoming a leader in the stent business

 

Consortium

Companies: Cardiatis, BIO.be

Universities: UNamur, UCLouvain, Université Libre de Bruxelles, UMons

 

Contact:

Noureddine Frid: [email protected]

Website: www.cardiatis.com